Cellid, Co., Ltd.

A299660

KR7299660001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 17/06/2024 am IST			5-day change	1st Jan Change
2,580 ^KRW	-2.82%		-7.69%	-42.28%

2023	Cellid, Co., Ltd.(KOSDAQ:A299660) dropped from S&P Global BMI Index	CI
2021	Private S.Korea firms plan $5.4 billion investment to create vaccine hub	RE

Cellid, Co., Ltd. announced that it has received KRW 19 billion in funding

March 19, 2021

On March 19, 2021, Cellid, Co., Ltd. (KOSDAQ:A299660) closed the transaction.

Latest news about Cellid, Co., Ltd.

Cellid, Co., Ltd.(KOSDAQ:A299660) dropped from S&P Global BMI Index	18/23/18	CI
Private S.Korea firms plan $5.4 billion investment to create vaccine hub	02/21/02	RE
SK bioscience : S.Korea to begin producing Novavax COVID-19 vaccine as early as June	12/21/12	RE
Cellid, Co., Ltd. announced that it has received KRW 19 billion in funding	19/21/19	CI
Cellid, Co., Ltd. announced that it expects to receive KRW 19 billion in funding	17/21/17	CI
Cellid, Inc.(KOSDAQ:A299660) added to S&P Global BMI Index	24/19/24	CI
Cellid, Inc.(KOSDAQ:A299660) added to S&P Global BMI Index	24/19/24	CI
Cellid, Inc.(KOSDAQ:A299660) added to S&P Global BMI Index	24/19/24	CI
Cellid, Inc. has completed an IPO in the amount of KRW 39.6 billion.	15/19/15	CI
Cellid, Inc. has filed an IPO.	18/18/18	CI
Cellid Co., Ltd. announced that it has received KRW 1.50 billion in funding from Amicogen Inc.	11/14/11	CI
Cellid Co., Ltd. announced that it expects to receive KRW 1.50 billion in funding from Amicogen Inc.	10/14/10	CI

Cellid, Co., Ltd. is a Korea-based company mainly engaged in the research and development of cancer therapeutic vaccine. The Company develops cancer therapeutic vaccine through development and clinical research of BVAC pipeline products using CeliVax original technology.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CELLID, CO., LTD.	-42.28%	2.61Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.42%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.02%	11TCr
ARGENX SE	+3.52%	2.29TCr
BEIGENE, LTD.	-11.63%	1.7TCr
GENMAB A/S	-16.50%	1.69TCr
WUXI APPTEC CO., LTD.	-39.57%	1.69TCr
NEUROCRINE BIOSCIENCES, INC.	+2.68%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+21.16%	1.16TCr
INSMED INCORPORATED	+108.78%	1.03TCr